Year: 2021

news_6

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development...

news_6

Bio-Thera Solutions Announces the First Patient Dosed in Phase III Clinical Trial for BAT2206, a Proposed Biosimilar of Stelara® (Ustekinumab)

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage pharmaceutical company, today announced that the first patient has been dosed in...

news_6

Seoul Viosys’ Violeds Technology Proves 99% Disinfection of COVID-19 Delta Variant in a Second to Support Airborne Viruses Prevention

ANSAN, South Korea--(BUSINESS WIRE)--#AirborneVirusesPrevention--  Seoul Viosys (KOSDAQ: 092190), the leading global compound semiconductor device provider and subsidiary of Seoul Semiconductor,...